ATE253930T1 - Behandlung von follikulären lymphomen unter verwendung von inhibitoren des lymphotoxin (lt)- aktivierungsweges - Google Patents

Behandlung von follikulären lymphomen unter verwendung von inhibitoren des lymphotoxin (lt)- aktivierungsweges

Info

Publication number
ATE253930T1
ATE253930T1 AT99903480T AT99903480T ATE253930T1 AT E253930 T1 ATE253930 T1 AT E253930T1 AT 99903480 T AT99903480 T AT 99903480T AT 99903480 T AT99903480 T AT 99903480T AT E253930 T1 ATE253930 T1 AT E253930T1
Authority
AT
Austria
Prior art keywords
lymphotoxin
treatment
follicular lymphomas
pathway inhibitors
activation pathway
Prior art date
Application number
AT99903480T
Other languages
English (en)
Inventor
Jeffrey Browning
Jeanette Thorbecke
Vincent Tsiagbe
Original Assignee
Biogen Inc
Univ New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc, Univ New York filed Critical Biogen Inc
Application granted granted Critical
Publication of ATE253930T1 publication Critical patent/ATE253930T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C07K14/5255—Lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C07K16/242—Lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT99903480T 1998-01-30 1999-01-29 Behandlung von follikulären lymphomen unter verwendung von inhibitoren des lymphotoxin (lt)- aktivierungsweges ATE253930T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7311298P 1998-01-30 1998-01-30
US7341098P 1998-02-02 1998-02-02
PCT/US1999/001928 WO1999038525A1 (en) 1998-01-30 1999-01-29 Treatment of follicular lymphomas using inhibitors of the lymphotoxin (lt) pathway

Publications (1)

Publication Number Publication Date
ATE253930T1 true ATE253930T1 (de) 2003-11-15

Family

ID=26754147

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99903480T ATE253930T1 (de) 1998-01-30 1999-01-29 Behandlung von follikulären lymphomen unter verwendung von inhibitoren des lymphotoxin (lt)- aktivierungsweges

Country Status (24)

Country Link
EP (1) EP1051187B9 (de)
JP (2) JP4713733B2 (de)
KR (1) KR100622960B1 (de)
CN (1) CN1287853C (de)
AT (1) ATE253930T1 (de)
AU (1) AU752710B2 (de)
BR (1) BR9908214A (de)
CA (1) CA2319698A1 (de)
CZ (1) CZ301026B6 (de)
DE (1) DE69912743T2 (de)
DK (1) DK1051187T3 (de)
EA (1) EA003862B1 (de)
EE (1) EE05235B1 (de)
ES (1) ES2211035T3 (de)
HU (1) HU226044B1 (de)
IL (2) IL137489A0 (de)
IS (1) IS2254B (de)
NO (1) NO328116B1 (de)
NZ (1) NZ506529A (de)
PL (1) PL203279B1 (de)
PT (1) PT1051187E (de)
SK (1) SK285725B6 (de)
TR (2) TR200101693T2 (de)
WO (1) WO1999038525A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL353057A1 (en) * 1999-06-28 2003-10-06 Basf Aktiengesellschaft Method for preventing tumoral growth
US7148061B2 (en) 2000-02-11 2006-12-12 The United States Of America As Represented By The Department Of Health And Human Services Identification of a novel domain in the tumor necrosis factor receptor family that mediates pre-ligand receptor assembly and function
PL366307A1 (en) 2000-10-13 2005-01-24 Biogen, Inc. Humanized anti-lt-beta-r antibodies
CN101259120B (zh) 2002-03-04 2012-07-04 Hdac默克研究有限责任公司 辛二酰苯胺异羟肟酸或其可药用盐在制备诱导末期分化的药物的用途
US7456219B2 (en) 2002-03-04 2008-11-25 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
CA2491480A1 (en) 2002-07-01 2004-01-08 Biogen, Inc. Humanized anti-lymphotoxin beta receptor antibodies
WO2004016317A1 (en) * 2002-08-14 2004-02-26 Erasmus University Medical Center Rotterdam Use of murine genomic regions identified to be involved in tumor development for the development of anti-cancer drugs and diagnosis of cancer
NZ538509A (en) * 2002-08-14 2007-11-30 Univ Erasmus Medical Ct Use of murine genomic regions identified to be involved in tumor development for the development of anit-cancer drugs and diagnosis of cancer
NZ544924A (en) 2003-06-27 2009-03-31 Biogen Idec Inc Modified binding molecules comprising connecting peptides
KR20060132006A (ko) 2004-03-23 2006-12-20 비오겐 아이덱 엠에이 아이엔씨. 수용체 커플링제 및 이의 치료적 용도
WO2006074399A2 (en) 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
CN101073665B (zh) * 2006-05-17 2014-11-26 上海复旦张江生物医药股份有限公司 淋巴毒素在制备增加化疗药物敏感性的药物中的应用
CN101600450A (zh) 2006-10-20 2009-12-09 比奥根艾迪克Ma公司 利用可溶性淋巴毒素β受体的脱髓鞘病的治疗

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747023A (en) * 1994-07-01 1998-05-05 Genentech, Inc. Cancer therapy using lymphotoxin
US5925351A (en) * 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
CA2229449A1 (en) * 1997-04-25 1998-10-25 Takeda Chemical Industries, Ltd. Novel receptor protein and its use

Also Published As

Publication number Publication date
PL342063A1 (en) 2001-05-21
EA003862B1 (ru) 2003-10-30
DE69912743D1 (de) 2003-12-18
TR200101693T2 (tr) 2002-06-21
CN1287853C (zh) 2006-12-06
IL137489A0 (en) 2001-07-24
AU2348899A (en) 1999-08-16
CZ301026B6 (cs) 2009-10-14
EA200000798A1 (ru) 2001-02-26
DE69912743T2 (de) 2004-09-23
WO1999038525A1 (en) 1999-08-05
JP2010235621A (ja) 2010-10-21
EE05235B1 (et) 2009-12-15
AU752710B2 (en) 2002-09-26
EP1051187B9 (de) 2004-08-11
HUP0102363A3 (en) 2004-04-28
PL203279B1 (pl) 2009-09-30
EP1051187A1 (de) 2000-11-15
ES2211035T3 (es) 2004-07-01
NO328116B1 (no) 2009-12-14
SK11302000A3 (sk) 2001-01-18
IL137489A (en) 2010-05-31
KR20010040497A (ko) 2001-05-15
CN1289252A (zh) 2001-03-28
HU226044B1 (en) 2008-03-28
JP4713733B2 (ja) 2011-06-29
EE200000446A (et) 2001-08-15
HK1029944A1 (en) 2001-04-20
HUP0102363A2 (hu) 2001-10-28
DK1051187T3 (da) 2004-03-08
BR9908214A (pt) 2000-11-28
SK285725B6 (sk) 2007-07-06
CA2319698A1 (en) 1999-08-05
NO20003848D0 (no) 2000-07-27
IS5570A (is) 2000-07-21
TR200002203T2 (tr) 2000-12-21
EP1051187B1 (de) 2003-11-12
NZ506529A (en) 2002-12-20
NO20003848L (no) 2000-10-02
PT1051187E (pt) 2004-03-31
JP2002501902A (ja) 2002-01-22
CZ20002751A3 (cs) 2000-12-13
IS2254B (is) 2007-06-15
KR100622960B1 (ko) 2006-09-12

Similar Documents

Publication Publication Date Title
MY151032A (en) Treatment of tnf? related disorders
DK0971713T3 (da) Anvendelse af cholinesteraseinhibitorer til behandling af opmærksomhedsforstyrrelser
ATE279181T1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
ES2153337T1 (es) Inhibidores de raf-quinasa.
EA200101166A1 (ru) Ингибиторы металлопротеаз
TR200003206T2 (tr) İndol türevleri ve patolojik hücre çoğalmasının neden olduğu habis hastalıklar ve diğer hastalıkların tedavisinde kullanımları.
YU21702A (sh) Supstituisani indoli za moduliranje nfkb aktivnosti
DE60022692D1 (de) (S,S)-Reboxetin zur Behandlung von Migränekopfschmerzen
ATE350030T1 (de) Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
TR200003514T2 (tr) Pirol ikame edilmiş 2-indolinon protein kinaz inhibitörleri
ATE253930T1 (de) Behandlung von follikulären lymphomen unter verwendung von inhibitoren des lymphotoxin (lt)- aktivierungsweges
DE69825286D1 (de) Verwendung von cholinesterasehemmern zur behandlung von aufmerksamkeitsmangel-störungen
ATE210447T1 (de) Verwendung von cck-b rezeptor antagonisten zur behandlung von schlafstörungen
ATE302002T1 (de) Verwendung von pyrazolderivaten zur behandlung von unfruchtbarkeit
ATE353667T1 (de) Verwendung von proteasom-inhibitoren zur behandlung des trockenen auges
DE60131968D1 (de) PYRANOÄ2,3-cÜIMIDAZOÄ1,2-aÜPYRIDIN-DERIVATE ZUR BEHANDLUNG VON GASTROINTESTINALEN ERKRANKUNGEN
ATE333277T1 (de) Behandlung von dyskinesie
DE60019946D1 (de) Antisense-modulation von x-verbundenen inhibitoren der apoptosis-expression
ATE322898T1 (de) Inhibitoren von mycobakterien
ATE320255T1 (de) Tie2 rezeptor-kinase-inhibitoren zur behandlung von angiogenen erkrankungen
DE60220825D1 (de) Verwendung von norepinephrinwiederaufnahmehemmern zur behandlung von ticks
ATE482217T1 (de) Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen
ATE291434T1 (de) Verwendung von angiotensin zur behandlung von krebsmetastasierung
ATE272406T1 (de) Prognose von ptp lar vermittelten krankheiten

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1051187

Country of ref document: EP